Precision medicine has advanced significantly over the past two decades—but most biologics for autoimmune and inflammatory diseases still start acting systemically, resulting in dose-limiting toxicities, off-target effects, and poor therapeutic windows.

TregShield Bio is bridging this precision gap bringing spatial activity precision to Biologics.

Our approach ensures that immune-modulating biologics remain inactive in circulation and activate only in diseased tissues. This next-level precision significantly expands the therapeutic index of biologics, enabling more effective treatment without compromising safety.

By delivering localized activity with systemic safety, we are redefining what’s possible in the treatment of I&I diseases.